1
NUR 635 Advanced Pharmacology Final Exams
2026/2027 Actual Exam | 3 Versions 1 2 & 3 with
Questions & Correct Answers with Detailed
Rationales | Grand Canyon University | Pass
Guaranteed - A+ Graded
Version 1: Pharmacokinetics and Pharmacodynamics
Q1: A patient with hepatic cirrhosis requires treatment for hypertension. The prescriber chooses
lisinopril over propranolol. This selection is MOST likely based on understanding of which
pharmacokinetic principle?
A. First-pass effect [CORRECT]
B. Protein binding displacement
C. Renal clearance
D. Volume of distribution
Correct Answer: A
Rationale: Propranolol undergoes extensive first-pass metabolism in the liver, making its
bioavailability unpredictable in patients with hepatic impairment. Lisinopril does not require
hepatic activation and is excreted renally, making it safer in liver disease. Options B, C, and D
are less relevant in this clinical decision.
Q2: A patient is taking a drug that is a substrate of the CYP3A4 enzyme system. They are
prescribed a new medication known to be a potent inhibitor of CYP3A4. The prescriber should
anticipate the need to:
A. Increase the dose of the substrate drug
B. Decrease the dose of the substrate drug [CORRECT]
C. Administer the drugs at opposite ends of the day
D. Switch the substrate drug to an IV formulation
,2
Correct Answer: B
Rationale: A CYP3A4 inhibitor decreases the metabolism of the substrate drug, leading to
increased plasma levels and potential toxicity. Therefore, the dose of the substrate drug should
generally be decreased to avoid adverse effects.
Q3: Which of the following statements accurately describes the concept of "steady state" in
pharmacokinetics?
A. It is achieved after one half-life of the drug
B. It is the point at which the drug is completely eliminated from the body
C. It occurs when the rate of drug administration equals the rate of elimination [CORRECT]
D. It requires a loading dose to be achieved
Correct Answer: C
Rationale: Steady state is the pharmacokinetic equilibrium where the amount of drug entering the
body equals the amount being eliminated. It is typically achieved after 4 to 5 half-lives of
continuous dosing.
Q4: A patient with chronic kidney disease (CKD) stage 4 has a creatinine clearance (CrCl) of 15
mL/min. The prescriber needs to prescribe an antibiotic that is 80% renally excreted unchanged.
The most appropriate action is:
A. Prescribe the standard dose
B. Increase the dosing interval or decrease the dose [CORRECT]
C. Administer the drug intravenously only
D. Avoid all antibiotics in this class
Correct Answer: B
Rationale: In renal impairment, the clearance of drugs excreted by the kidneys is reduced. To
prevent accumulation and toxicity, the dosing interval is usually extended (e.g., q24h instead of
q12h), or the individual dose is reduced.
,3
Q5: A drug with a half-life of 12 hours is prescribed for a patient. The prescriber advises the
patient that steady-state levels will likely be achieved in approximately:
A. 12 hours
B. 24 hours
C. 48 to 60 hours [CORRECT]
D. 72 to 96 hours
Correct Answer: C
Rationale: Steady state is generally reached in 4 to 5 half-lives. For a drug with a 12-hour half-
life: 12 x 4 = 48 hours and 12 x 5 = 60 hours.
Q6: A nurse practitioner understands that a drug with a "narrow therapeutic index" (NTI)
requires:
A. Less frequent monitoring
B. A wider margin of safety
C. Careful dosing and frequent plasma level monitoring [CORRECT]
D. High doses to achieve efficacy
Correct Answer: C
Rationale: NTI drugs (e.g., digoxin, warfarin, lithium, phenytoin) have a small margin between
the therapeutic dose and the toxic dose. This necessitates precise dosing and therapeutic drug
monitoring (TDM) to ensure safety and efficacy.
Q7: A patient is started on warfarin, which is highly protein-bound. The patient is currently
taking another highly protein-bound drug, such as valproic acid. The nurse practitioner should
monitor for:
A. Decreased effectiveness of warfarin
B. Increased free warfarin levels and risk of bleeding [CORRECT]
C. Increased metabolism of warfarin
, 4
D. Rapid elimination of valproic acid
Correct Answer: B
Rationale: When two highly protein-bound drugs are co-administered, they compete for binding
sites. This displacement increases the concentration of "free" (active) drug, potentially leading to
toxicity (bleeding risk in this case).
Q8: The route of administration that bypasses the first-pass effect entirely is:
A. Oral
B. Sublingual [CORRECT]
C. Rectal (suppository)
D. Intramuscular
Correct Answer: B
Rationale: Sublingual administration allows the drug to be absorbed directly into the venous
circulation via the mucous membranes, bypassing the hepatic portal system and the first-pass
metabolism by the liver.
Q9: Which of the following describes a Phase I drug metabolism reaction?
A. Conjugation with glucuronic acid
B. Reduction, Oxidation, or Hydrolysis [CORRECT]
C. Synthesis of a larger molecule
D. Usually results in a less active metabolite
Correct Answer: B
Rationale: Phase I metabolism involves functionalization reactions (oxidation, reduction,
hydrolysis) usually mediated by CYP enzymes. It often results in a metabolite that is more polar.
Phase II involves conjugation.
NUR 635 Advanced Pharmacology Final Exams
2026/2027 Actual Exam | 3 Versions 1 2 & 3 with
Questions & Correct Answers with Detailed
Rationales | Grand Canyon University | Pass
Guaranteed - A+ Graded
Version 1: Pharmacokinetics and Pharmacodynamics
Q1: A patient with hepatic cirrhosis requires treatment for hypertension. The prescriber chooses
lisinopril over propranolol. This selection is MOST likely based on understanding of which
pharmacokinetic principle?
A. First-pass effect [CORRECT]
B. Protein binding displacement
C. Renal clearance
D. Volume of distribution
Correct Answer: A
Rationale: Propranolol undergoes extensive first-pass metabolism in the liver, making its
bioavailability unpredictable in patients with hepatic impairment. Lisinopril does not require
hepatic activation and is excreted renally, making it safer in liver disease. Options B, C, and D
are less relevant in this clinical decision.
Q2: A patient is taking a drug that is a substrate of the CYP3A4 enzyme system. They are
prescribed a new medication known to be a potent inhibitor of CYP3A4. The prescriber should
anticipate the need to:
A. Increase the dose of the substrate drug
B. Decrease the dose of the substrate drug [CORRECT]
C. Administer the drugs at opposite ends of the day
D. Switch the substrate drug to an IV formulation
,2
Correct Answer: B
Rationale: A CYP3A4 inhibitor decreases the metabolism of the substrate drug, leading to
increased plasma levels and potential toxicity. Therefore, the dose of the substrate drug should
generally be decreased to avoid adverse effects.
Q3: Which of the following statements accurately describes the concept of "steady state" in
pharmacokinetics?
A. It is achieved after one half-life of the drug
B. It is the point at which the drug is completely eliminated from the body
C. It occurs when the rate of drug administration equals the rate of elimination [CORRECT]
D. It requires a loading dose to be achieved
Correct Answer: C
Rationale: Steady state is the pharmacokinetic equilibrium where the amount of drug entering the
body equals the amount being eliminated. It is typically achieved after 4 to 5 half-lives of
continuous dosing.
Q4: A patient with chronic kidney disease (CKD) stage 4 has a creatinine clearance (CrCl) of 15
mL/min. The prescriber needs to prescribe an antibiotic that is 80% renally excreted unchanged.
The most appropriate action is:
A. Prescribe the standard dose
B. Increase the dosing interval or decrease the dose [CORRECT]
C. Administer the drug intravenously only
D. Avoid all antibiotics in this class
Correct Answer: B
Rationale: In renal impairment, the clearance of drugs excreted by the kidneys is reduced. To
prevent accumulation and toxicity, the dosing interval is usually extended (e.g., q24h instead of
q12h), or the individual dose is reduced.
,3
Q5: A drug with a half-life of 12 hours is prescribed for a patient. The prescriber advises the
patient that steady-state levels will likely be achieved in approximately:
A. 12 hours
B. 24 hours
C. 48 to 60 hours [CORRECT]
D. 72 to 96 hours
Correct Answer: C
Rationale: Steady state is generally reached in 4 to 5 half-lives. For a drug with a 12-hour half-
life: 12 x 4 = 48 hours and 12 x 5 = 60 hours.
Q6: A nurse practitioner understands that a drug with a "narrow therapeutic index" (NTI)
requires:
A. Less frequent monitoring
B. A wider margin of safety
C. Careful dosing and frequent plasma level monitoring [CORRECT]
D. High doses to achieve efficacy
Correct Answer: C
Rationale: NTI drugs (e.g., digoxin, warfarin, lithium, phenytoin) have a small margin between
the therapeutic dose and the toxic dose. This necessitates precise dosing and therapeutic drug
monitoring (TDM) to ensure safety and efficacy.
Q7: A patient is started on warfarin, which is highly protein-bound. The patient is currently
taking another highly protein-bound drug, such as valproic acid. The nurse practitioner should
monitor for:
A. Decreased effectiveness of warfarin
B. Increased free warfarin levels and risk of bleeding [CORRECT]
C. Increased metabolism of warfarin
, 4
D. Rapid elimination of valproic acid
Correct Answer: B
Rationale: When two highly protein-bound drugs are co-administered, they compete for binding
sites. This displacement increases the concentration of "free" (active) drug, potentially leading to
toxicity (bleeding risk in this case).
Q8: The route of administration that bypasses the first-pass effect entirely is:
A. Oral
B. Sublingual [CORRECT]
C. Rectal (suppository)
D. Intramuscular
Correct Answer: B
Rationale: Sublingual administration allows the drug to be absorbed directly into the venous
circulation via the mucous membranes, bypassing the hepatic portal system and the first-pass
metabolism by the liver.
Q9: Which of the following describes a Phase I drug metabolism reaction?
A. Conjugation with glucuronic acid
B. Reduction, Oxidation, or Hydrolysis [CORRECT]
C. Synthesis of a larger molecule
D. Usually results in a less active metabolite
Correct Answer: B
Rationale: Phase I metabolism involves functionalization reactions (oxidation, reduction,
hydrolysis) usually mediated by CYP enzymes. It often results in a metabolite that is more polar.
Phase II involves conjugation.
